Genzyme and to-BBB Collaborate on Brain Delivery of Biologics for Neurodegenerative Diseases

November 12, 2009

Brain drug delivery company to-BBB, (Leiden, The Netherlands) has entered into a research collaboration with Genzyme Corporation (Cambridge, MA) to evaluate to-BBB?s proprietary G-Technology to enhance delivery of biologics for neurodegenerative diseases.

Brain drug delivery company to-BBB, (Leiden, The Netherlands) has entered into a research collaboration with Genzyme Corporation (Cambridge, MA) to evaluate to-BBB’s proprietary G-Technology to enhance delivery of biologics for neurodegenerative diseases.

G-Technology is designed to transport different classes of drugs across the blood-brain barrier by formulating these drugs into proprietary glutathione coated liposomes. The company has shown proof of concept in different disease models and Genzyme will now evaluate the technology in its disease models.

The disease modifying properties of biological drugs like peptides, enzymes, and antibodies have become well established in the last decades as important medicines. The treatment of brain diseases with these modern treatments is unfortunately hampered by the inability of such drugs to easily pass the blood-brain barrier.